Linked Data API

Show Search Form

Search Results

752468
star this property registered interest false more like this
star this property date less than 2017-07-17more like thismore than 2017-07-17
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Parkinson's Disease: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text Her Majesty's Government how much the NHS pays for a one year supply of Apomorphine for a patient with Parkinson's Disease; how much they estimate it costs to manufacture a year's supply of that drug; what assessment they have made of the difficulties of manufacturing Apomorphine to clinical standards; and whether they intend to take any steps to reduce the cost of that drug to the NHS. more like this
star this property tabling member printed
Lord Lucas more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin HL914 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>The drug cost to the National Health Service for a one year supply of Apomorphine for a patient with Parkinson's Disease is estimated to be in the region of £5,300 and £9,000, based on the usual daily dose of 3 – 30mg. However, the maximum daily is 100mg, so the annual cost for some patient’s treatment may be higher.</p><p>We have no estimate of the cost of manufacture. We are not aware of any particular issues relating to the manufacture of this drug. Pharmaceutical companies participate in either the voluntary pharmaceutical price regulation scheme (PPRS) or the statutory medicines price regulation scheme, both of which regulate the cost of medicines to the NHS. Products covered by the statutory scheme are subject to a 15% cut to their list price. Companies in the PPRS pay a percentage of sales to the Government when growth in NHS spending on medicines exceeds an agreed level. NHS purchasers may also negotiate discounts with pharmaceutical companies in addition to national price regulation.</p><p> </p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
remove filter
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
1879
star this property label Biography information for Lord Lucas more like this